ELITE PHARMACEUTICAL
ELI
ELI was delisted on the 20th of May, 2009.
0 hedge funds and large institutions have $0 invested in ELITE PHARMACEUTICAL in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
100% less funds holding
Funds holding: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $24K → $0 (-$24K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFAG
Blackston Financial Advisory Group
The Villages,
Florida
|
-$21K |
| 2 |
Fisher Asset Management
Camas,
Washington
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFAG
1
Blackston Financial Advisory Group
The Villages,
Florida
| – | -$21K | -577,605 | Closed |
|
|
2
Fisher Asset Management
Camas,
Washington
| – | -$3K | -82,000 | Closed |
|
ELI Hedge Fund Activity: Q4 2022 in Review
0 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q4 2022, worth a combined $0 — down 100% from $24K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ELI and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Blackston Financial Advisory Group, exiting entirely with an estimated $21K sold.
- 0 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q4 2022, down from 2 in Q3 2022.
- Funds reported $0 of ELITE PHARMACEUTICAL stock for Q4 2022, down 100% quarter-over-quarter.
- 0 funds opened new ELITE PHARMACEUTICAL positions in Q4 2022 and 2 closed out, a net change of -2 holders.
- The largest ELITE PHARMACEUTICAL seller in Q4 2022 was Blackston Financial Advisory Group, an estimated $21K sold.
Based on aggregated 13F filings for Q4 2022.